Form 4: Rigel Pharmaceuticals Director Executes Stock Sale

Director Kamil Ali-Jackson sold 2,500 shares of Rigel Pharmaceuticals common stock on May 26, 2026.

Summary

• Director Kamil Ali-Jackson sold 2,500 shares of Rigel Pharmaceuticals (RIGL) common stock.
• The transaction was executed at a price of $29.17 per share.
• Following the sale, the director retains 12,625 shares of common stock.
• The sale was conducted under a pre-established Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-arranged 10b5-1 plan, which is a standard administrative procedure for corporate insiders.

Positives

• The transaction was executed via a pre-planned Rule 10b5-1 trading plan, which typically indicates the sale is for personal financial planning rather than a reaction to non-public information.

Negatives

• The sale represents a reduction in the director's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on current valuation.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a standard practice for corporate directors and executives to diversify personal holdings and does not necessarily reflect a change in the company's fundamental outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to sell shares while avoiding potential accusations of insider trading.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the director's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, Insider Trading, Form 4, Kamil Ali-Jackson, Biotech